Physician profile
Eric Thomason
NPI 1528425501
$333,405.33
in general payments reported to CMS, 2019-2025
16 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.23 · 2022: $31K · 2023: $72K · 2024: $115K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $214K · Consulting Fee: $41K · Travel and Lodging: $37K · Food and Beverage: $9,599 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $214,241.54 |
| Consulting Fee | $41,128.25 |
| Travel and Lodging | $37,075.03 |
| Food and Beverage | $9,599.21 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $222,232.28 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $60,335.08 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $40,344.03 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $5,226.79 | 2022-2025 | Lybalvi, Aristada |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,216.38 | 2024 | Abilify Mycite |
| Lundbeck LLC | $292.98 | 2023-2025 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $186.65 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $147.51 | 2025 | Austedo Xr |
| Novo Nordisk INC | $124.60 | 2024 | Wegovy |
| Dexcom, INC. | $122.93 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Sunovion Pharmaceuticals INC. | $72.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.33 | 2024-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.29 | 2025 | Caplyta |
| Corium, LLC | $15.79 | 2023 | Azstarys |
| Braeburn INC. | $13.76 | 2025 | Brixadi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thomason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.